GA
AZN icon

GFS Advisors’s AstraZeneca AZN Stock Holding History

GFS Advisors’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-2,800
Closed -$222K – 122
2018
Q3 		$222K Sell
2,800
-4,250
-60% -$321K 0.06% 123
2018
Q2 		$495K Hold
7,050
– – 0.1% 111
2018
Q1 		$493K Sell
7,050
-4,613
-40% -$320K 0.1% 110
2017
Q4 		$809K Sell
11,663
-3,950
-25% -$266K 0.18% 89
2017
Q3 		$1.06M Sell
15,613
-5,204
-25% -$329K 0.24% 79
2017
Q2 		$1.42M Sell
20,817
-4,415
-17% -$288K 0.31% 62
2017
Q1 		$1.57M Buy
+25,232
New +$1.47M 0.32% 59

Other funds holding AZN

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

GFS Advisors's AZN Position: Q4 2018 in Review

GFS Advisors sold out of AstraZeneca (AZN) in Q4 2018, closing a stake of 2,800 shares — an estimated $222K sold.

GFS Advisors first reported a position in AZN in Q1 2017 and held it in 7 quarters. The position peaked at $1.57M in Q1 2017. 557 funds tracked by Wall St. Rank hold AZN as of Q4 2018.

  • GFS Advisors reported no remaining AstraZeneca position as of Q4 2018 after selling out during the quarter.
  • GFS Advisors sold 2,800 AstraZeneca shares in Q4 2018, an estimated $222K.
  • GFS Advisors first reported a position in AstraZeneca in Q1 2017 and held it in 7 quarters.
  • GFS Advisors's AstraZeneca position peaked at $1.57M in Q1 2017.
  • 557 funds tracked by Wall St. Rank held AstraZeneca as of Q4 2018.

Based on GFS Advisors's 13F filing for Q4 2018, filed 12 Feb 2019.